Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19783996
Gonfloni S, et al. (2009) Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med 15, 1179-85 19783996
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
adriamycin increase
etoposide increase

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
adriamycin increase
etoposide increase

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
adriamycin no change compared to control
etoposide no change compared to control

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  bone cancer
Relevant cell lines - cell types - tissues:  Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
adriamycin no change compared to control
etoposide no change compared to control

Y149-p - p63 (human)
Modsite: SVTAPSPyAQPSSTF SwissProt Entrez-Gene
Orthologous residues
p63 (human): Y149‑p, p63 iso2 (human): Y55‑p, p63 (mouse): Y149‑p, p63 (rat): Y149‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  293T (epithelial), NCI-H1299 (pulmonary), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Abl (human) transfection of constitutively active enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
imatinib cisplatin inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  protein stabilization
Effect of modification (process):  transcription, altered

Y171-p - p63 (human)
Modsite: AIPSNTDyPGPHSFD SwissProt Entrez-Gene
Orthologous residues
p63 (human): Y171‑p, p63 iso2 (human): Y77‑p, p63 (mouse): Y171‑p, p63 (rat): Y171‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  293T (epithelial), NCI-H1299 (pulmonary), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Abl (human) transfection of constitutively active enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
imatinib cisplatin inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  protein stabilization

Y290-p - p63 (human)
Modsite: RQSVLVPyEPPQVGT SwissProt Entrez-Gene
Orthologous residues
p63 (human): Y290‑p, p63 iso2 (human): Y196‑p, p63 (mouse): Y290‑p, p63 (rat): Y290‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  bone cancer, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  293T (epithelial), NCI-H1299 (pulmonary), Saos-2 (bone cell)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Abl (human) transfection of constitutively active enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cisplatin increase
imatinib cisplatin inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  protein stabilization